Luciano Costa, Rakesh Popat, David Siegel, Fredrik Schjesvold, Saad Usmani, Nizar J. Bahlis, Albert Oriol, Michael Chu, Syed Abbas Ali, Karthik Ramasamy, Monique Hartley-Brown, Joaquín Martínez-Lopez, Allison Gaudy, Antonina Kurtova, Wen Zhang, Rafael Sarmiento, August Dietrich, Jessica Katz, Michael Pourdehnad, Paul Richardson
OA-29 Mezigdomide (MEZI), Tazemetostat (TAZ), and Dexamethasone (DEX) in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results From the CA057-003 Trial
期刊介绍:
Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.